Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Insight, 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Juvenile Macular Degeneration (Stargardt Disease) development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Juvenile Macular Degeneration (Stargardt Disease) pipeline products by developmental stage, product type, molecule type, and administration route.
ScopeThe report provides a snapshot of the pipeline development for the Juvenile Macular Degeneration (Stargardt Disease) The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Juvenile Macular Degeneration (Stargardt Disease) The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Juvenile Macular Degeneration (Stargardt Disease) The report also covers the dormant and discontinued pipeline projects related to the Juvenile Macular Degeneration (Stargardt Disease)
Reasons to PurchaseEstablish comprehensive understanding of the pipeline activity across this Juvenile Macular Degeneration (Stargardt Disease) to formulate effective R&D strategies Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Juvenile Macular Degeneration (Stargardt Disease) therapeutics Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress
Companies FeaturedAstellas Pharma Acucela Inc. Alkeus Pharmaceuticals Inc. Katairo Astellas Pharma Inc. Copernicus Therapeutics Inc. Grupo Ferrer Internacional S.A. Iris Pharma
Key Topics Covered
1. Report Introduction
2. Juvenile Macular Degeneration (Stargardt Disease) Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease)
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name : Company NameProduct Description Research and Development Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company NameProduct Description Research and Development Product Development Activities
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company NameProduct Description Research and Development Product Development Activities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5vggpw/juvenile_macular?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005354/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Optical Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/30/2018 11:49 AM/DISC: 11/30/2018 11:49 AM